Press Releases

Date Title  
Jul 23, 2019
- Celgene licenses JTX-8064, resulting in $50.0 million upfront payment to Jounce - - Jounce retains full worldwide rights to vopratelimab, JTX‑4014 and all discovery programs - - Company to host conference call and webcast today at 5:00 p.m. ET - CAMBRIDGE, Mass.
Jun 18, 2019
- Commenced patient enrollment in Phase 2 clinical trial of vopratelimab in combination with ipilimumab - - Preliminary efficacy and relationship to biomarker data expected in 2020 - CAMBRIDGE, Mass. , June 18, 2019 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc.
Jun 11, 2019
CAMBRIDGE, Mass. , June 11, 2019 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced that Jounce management will present at two upcoming investor
May 8, 2019
- New data from vopratelimab and JTX-8064 presented at AACR 2019 - - On track to initiate new Phase 2 studies of vopratelimab - - Ended the quarter with $173.2 million in cash, cash equivalents and investments - - Company to host conference call and webcast today at 8:00 AM ET - CAMBRIDGE, Mass.
May 1, 2019
CAMBRIDGE, Mass. , May 01, 2019 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced that it will report first quarter 2019 financial results and
Apr 3, 2019
Preclinical data supports the development of JTX-8064 as a novel immunotherapy to reprogram immune-suppressive macrophages and enhance anti-tumor immunity CAMBRIDGE, Mass. , April 03, 2019 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the
Apr 2, 2019
- Improved PFS and OS observed in patients treated with vopratelimab who have emergence of ICOS hi CD4 T cells compared to patients with ICOS lo CD4 T cells - - ICOS hi CD4 T cells demonstrate distinct, activated T effector cell characteristics - - Company to Host Investor Event and Live Webcast on
Mar 6, 2019
- New data from two programs to be presented at AACR - - New Phase 2 studies to be initiated in 2019 supported by established safety from dose escalation cohorts of vopratelimab (JTX-2011), with ipilimumab and with pembrolizumab - - Ended 2018 with $195.9 million in cash, cash equivalents and
Mar 4, 2019
CAMBRIDGE, Mass. , March 04, 2019 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced that Richard Murray , Ph.D., chief executive officer and
Feb 28, 2019
CAMBRIDGE, Mass. , Feb. 28, 2019 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced that it will report fourth quarter and full year 2018 financial
Feb 27, 2019
ICONIC Clinical Data Demonstrates Improved PFS/OS in Patients with Emergence of JTX-2011 Mechanistic Biomarker ( ICOS high CD4 T cells) Company to Host Investor Event and Live Webcast on Tuesday, April 2, 2019 CAMBRIDGE, Mass. , Feb. 27, 2019 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc.
Jan 3, 2019
Dose Escalation Trial in Patients with Solid Tumors CAMBRIDGE, Mass. , Jan. 03, 2019 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, announced today that the
Jan 2, 2019
CAMBRIDGE, Mass. , Jan. 02, 2019 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers for patient enrichment, today announced that Richard Murray , Ph.D., chief